Grant Number:	1R01CA155329-01 Interpret this number
Primary Investigator:	Basu, Anirban
Organization:	University Of Washington
Project Title:	Instrumental Variable Methods for Censored Cost Data and an Application in Prosta
Fiscal Year:	2011

DESCRIPTION (provided by applicant): There are many studies where the analytical task is to estimate the total costs over a defined period of time for a treatment group with a particular condition or chronic disease. These include cost of illness studies such as incremental or total lifetime costs for a disease, the components of cost effectiveness, and other forms of economic evaluation in health care. However, answering such questions requires addressing a range of statistical and econometric issues that include variable time periods of observation for individual patients, fluctuating costs over the course of the disease or treatment, the escalation of costs when the patient is dying and administrative censoring of data prior to the endpoint of interest (e.g. cure, death). These analytical obstacles are compounded by skewed cost data and the endogeneity of treatment decisions caused by self-selection into treatment based on expected idiosyncratic benefits, costs and risks of treatments. Our proposal will develop innovative methods to address each of these problems in a consolidated manner. The proposed work will advance four broad areas in the fields of cost analysis and economic evaluation in health studies. First, it will provide and validate a consistent method of estimating costs in a setting characterized by varying rates of spending over time, right censoring, and the escalation of expenditures commonly observed just before death. Second, it will bridge two large literatures on methods, one on modeling skewed cost data (with right censoring) and the other on the use of IV in the presence of treatment heterogeneity. Third, it can highlight the role that unobserved patient preferences and disease severity may have in generating treatment effect heterogeneity in the context of prostate cancer. Lastly, this work has a high likelihood of generating new information about the comparative cost estimates in prostate cancer which can serve as important inputs into cost-effectiveness and other policy analyses. PUBLIC HEALTH RELEVANCE: The proposed work will develop innovative methods that will advance four broad areas in the fields of cost analysis and economic evaluation in health studies. First, it will provide and validate a consistent method of estimating costs in a setting characterized by varying rates of spending over time, right censoring, and the escalation of expenditures commonly observed just before death. Second, it will bridge two large literatures on methods, one on modeling skewed cost data (with right censoring) and the other on the use of IV in the presence of treatment heterogeneity. Third, it can highlight the role that unobserved patient preferences and disease severity may have in generating treatment effect heterogeneity in the context of prostate cancer. Lastly, this work has a high likelihood of generating new information about the comparative cost estimates in prostate cancer which can serve as important inputs into cost-effectiveness and other policy analyses.




2SLS versus 2SRI: Appropriate methods for rare outcomes and/or rare exposures.
Authors: Basu A. , Coe N.B. , Chapman C.G. .
Source: Health Economics, 2018 06; 27(6), p. 937-955.
EPub date: 2018-03-26 00:00:00.0.
PMID: 29577493
Related Citations

Heterogeneity in the impact of type of schooling on adult health and lifestyle.
Authors: Basu A. , Jones A.M. , Dias P.R. .
Source: Journal Of Health Economics, 2017-11-24 00:00:00.0; 57, p. 1-14.
EPub date: 2017-11-24 00:00:00.0.
PMID: 29179025
Related Citations

Inference Using Sample Means of Parametric Nonlinear Data Transformations.
Authors: Terza J.V. .
Source: Health Services Research, 2016 Jun; 51(3), p. 1109-13.
PMID: 27091770
Related Citations

Welfare implications of learning through solicitation versus diversification in health care.
Authors: Basu A. .
Source: Journal Of Health Economics, 2015 Jul; 42, p. 165-73.
PMID: 25966453
Related Citations

Are Elderly Patients With Clinically Localized Prostate Cancer Overtreated? Exploring Heterogeneity in Survival Effects.
Authors: Basu A. , Gore J.L. .
Source: Medical Care, 2015 Jan; 53(1), p. 79-86.
PMID: 25397964
Related Citations

Long-term costs of introducing HPV-DNA post-treatment surveillance to national cervical cancer screening in Ireland.
Authors: Agapova M. , Duignan A. , Smith A. , O'Neill C. , Basu A. .
Source: Expert Review Of Pharmacoeconomics & Outcomes Research, 2015; 15(6), p. 999-1005.
PMID: 26377838
Related Citations

Can we make smart choices between OLS and contaminated IV methods?
Authors: Basu A. , Chan K.C. .
Source: Health Economics, 2014 Apr; 23(4), p. 462-72.
PMID: 23765683
Related Citations

Heterogeneity in action: the role of passive personalization in comparative effectiveness research.
Authors: Basu A. , Jena A.B. , Goldman D.P. , Philipson T.J. , Dubois R. .
Source: Health Economics, 2014 Mar; 23(3), p. 359-73.
PMID: 24123568
Related Citations

Highlighting differences between conditional and unconditional quantile regression approaches through an application to assess medication adherence.
Authors: Borah B.J. , Basu A. .
Source: Health Economics, 2013 Sep; 22(9), p. 1052-70.
PMID: 23616446
Related Citations

Patient-centered or 'central' patient: Raising the veil of ignorance over randomization.
Authors: Basu A. .
Source: Statistics In Medicine, 2012-11-10 00:00:00.0; 31(25), p. 3057-9; discussion 3066-7.
PMID: 23055182
Related Citations

Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs.
Authors: Basu A. , Meltzer H.Y. .
Source: Journal Of Comparative Effectiveness Research, 2012 Mar; 1(2), p. 171-80.
PMID: 24237376
Related Citations

Estimating Decision-Relevant Comparative Effects Using Instrumental Variables.
Authors: Basu A. .
Source: Statistics In Biosciences, 2011 Sep; 3(1), p. 6-27.
PMID: 22010051
Related Citations

ESTIMATING TREATMENT EFFECTS ON HEALTHCARE COSTS UNDER EXOGENEITY: IS THERE A 'MAGIC BULLET'?
Authors: Basu A. , Polsky D. , Manning W.G. .
Source: Health Services & Outcomes Research Methodology, 2011-07-01 00:00:00.0; 11(1-2), p. 1-26.
PMID: 22199462
Related Citations

ESTIMATING PERSON-CENTERED TREATMENT (PeT) EFFECTS USING INSTRUMENTAL VARIABLES: AN APPLICATION TO EVALUATING PROSTATE CANCER TREATMENTS.
Authors: Basu A. .
Source: Journal Of Applied Econometrics (chichester, England), 2014 June/July; 29(4), p. 671-691.
PMID: 25620844
Related Citations